135 related articles for article (PubMed ID: 9838910)
1. [Phase I study of raltitrexed (ZD-1694)].
Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
[TBL] [Abstract][Full Text] [Related]
2. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
3. [Phase I study of CI-898. CI-898 Study Group].
Taguchi T; Tsukagoshi S; Furue H; Niitani H; Ohta K; Ariyoshi H; Hasegawa K; Majima H; Nakao I; Yasutomi M
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1599-612. PubMed ID: 1831340
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
Clarke SJ; Hanwell J; de Boer M; Planting A; Verweij J; Walker M; Smith R; Jackman AL; Hughes LR; Harrap KR; Kennealey GT; Judson IR
J Clin Oncol; 1996 May; 14(5):1495-503. PubMed ID: 8622063
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of ZD1694 in patients with advanced gastric cancer.
Meropol NJ; Pazdur R; Vincent M; Willson JK; Kelsen DP; Douglass HO
Am J Clin Oncol; 1996 Dec; 19(6):628-30. PubMed ID: 8931686
[TBL] [Abstract][Full Text] [Related]
6. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
7. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Beale P; Judson I; Hanwell J; Berry C; Aherne W; Hickish T; Martin P; Walker M
Cancer Chemother Pharmacol; 1998; 42(1):71-6. PubMed ID: 9619761
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
9. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Lin JT; Cashmore AR; Baker M; Dreyer RN; Ernstoff M; Marsh JC; Bertino JR; Whitfield LR; Delap R; Grillo-Lopez A
Cancer Res; 1987 Jan; 47(2):609-16. PubMed ID: 2947679
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
[TBL] [Abstract][Full Text] [Related]
11. [Phase I clinical study of TT-62. Research group of TT-62].
Taguchi T; Furue H; Niitani H; Ohta K; Tsukagoshi S; Wakui A; Hasegawa K; Nakao I; Ohashi Y; Tominaga T
Gan To Kagaku Ryoho; 1993 Feb; 20(2):241-6. PubMed ID: 8434962
[TBL] [Abstract][Full Text] [Related]
12. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
[TBL] [Abstract][Full Text] [Related]
13. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
[TBL] [Abstract][Full Text] [Related]
14. [A phase I study on a weekly schedule of DWA2114R].
Niitani H; Fukuoka M; Furusawa M; Tamura M; Hasegawa K; Kurita Y; Ariyoshi Y; Matsunaga T; Kumoi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1027-32. PubMed ID: 1626938
[TBL] [Abstract][Full Text] [Related]
15. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
Nishi I; Yokoyama T; Nakao I; Harashima S; Ohashi Y; Kanko T; Saito T
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Rowinsky EK; Noe DA; Ettinger DS; Christian MC; Lubejko BG; Fishman EK; Sartorius SE; Boyd MR; Donehower RC
Cancer Res; 1993 Apr; 53(8):1794-801. PubMed ID: 8467498
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Kris MG; Kinahan JJ; Gralla RJ; Fanucchi MP; Wertheim MS; O'Connell JP; Marks LD; Williams L; Farag F; Young CW
Cancer Res; 1988 Oct; 48(19):5573-9. PubMed ID: 3416310
[TBL] [Abstract][Full Text] [Related]
18. [Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
Meguro S; Nagata T; Yokoyama K; Chinen T; Kobayashi T; Yamazaki H; Kuraishi Y; Ichiba ; Abe M; Isogai Y
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1818-22. PubMed ID: 6476844
[TBL] [Abstract][Full Text] [Related]
19. [A phase I study of DWA2114R].
Ariyoshi Y; Wakui A; Hasegawa K; Niitani H; Ogawa M; Sakai Y; Majima H; Furue H; Miyake H; Taguchi T
Gan To Kagaku Ryoho; 1992 May; 19(5):685-93. PubMed ID: 1580642
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of echinomycin administered on an intermittent bolus schedule.
Harvey JH; McFadden M; Andrews WG; Byrne PJ; Ahlgren JD; Woolley PV
Cancer Treat Rep; 1985 Dec; 69(12):1365-8. PubMed ID: 4075312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
